行情

ARRY

ARRY

Array生物制药
NASDAQ

实时行情|Nasdaq Last Sale

47.85
0.00
0.00%
已退市 09:30 11/20 EST
开盘
--
昨收
47.29
最高
--
最低
--
成交量
--
成交额
--
52周最高
47.98
52周最低
12.56
市值
106.11亿
市盈率(TTM)
-81.2394
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARRY 新闻

  • Heres How Pfizer Stock (and Pharma) Stand to Benefit From Mylan Deal
  • InvestorPlace.07/31 10:01
  • Array Shares To No Longer Trade As Pfizer Is Taking Over The Co.
  • Benzinga.07/30 12:21
  • Array BioPharma Shares Halted For Info Requested By Exchange
  • Benzinga.07/30 12:18
  • The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings
  • Benzinga.07/30 11:43

更多

所属板块

Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
-0.14%

热门股票

名称
价格
涨跌幅

ARRY 简况

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
展开

Webull提供Array Biopharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。